ArticleInternational urology and nephrology2026
Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
purposeTo evaluate the short-term efficacy and safety of finerenone in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD).
methodsA retrospective cohort study was conducted on a relatively small sample of 23 patients diagnosed with T1D and CKD between January 2023 and August 2024. All patients received renin-angiotensin system inhibitors (RASi), with 12 patients additionally treated with finerenone.
resultsThe cohort had a median age of 34 (29, 39) years, including 11 females. Median Hemoglobin A1c (HbA1c) was 7.30% (6.55, 8.10%), proteinuria was 1.49 (0.88, 2.84) g/24h, mean estimated glomerular filtration rate (eGFR) was 71.91 ± 24.59 mL/min/1.73m
conclusionIn this preliminary study, finerenone showed potential for attenuating kidney function decline in patients with T1D and CKD, though its long-term efficacy and safety require validation in larger trials.
Indexed as
Identifiers
40911177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.